Soleno Therapeutics has gained US approval for Vykat XR, making it the first ever drug to treat hyperphagia, an intense, persistent hunger experienced by people with the rare genetic disorder Prader-Willi syndrome (PWS).
Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
